Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Azeliragon in mild to moderate Alzheimer's disease
NCT00141661Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azeliragon in Alzheimer's disease (AD) (3 arms), sponsored by Pfizer. Primary endpoint: Adverse Events, Laboratory Tests, ECG at 10 weeks. Started Oct 2005; status: completed.
02
Drugs
azeliragon
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00141661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141661.